If an outside expert has more than $50,000 in ties to drug and medical device companies regulated by the Food and Drug Administration he will be barred from advising the FDA under the new draft guidelines. The money calculations include corporate grants, contracts, consulting fees and/or company stock. Although it was not clear how many advisors would be disqualified, Randall Lutter, the Food and Drug Administration’s acring commissioner for policy, said it was a “significant number.”
To read more click here. To learn more about drug company inducements as a violation of the False Claims Act, click here.